Drug class profile · refreshed daily from federal data

Progestin

10 molecules in this class, $60.0M combined CY2024 Part D spend across 1.5M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Progestin class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 10tracked in Part D
CY24 Part D spend: $60.0Mcombined across class
Total Rx claims: 1.5M550K unique beneficiaries
Generic mfrs (active): 58across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Megestrol

707K Part D claims (CY24) · 282K beneficiaries · First FDA approval: 1995-11-30

5 generic mfrs 545 plans require PA

Low NADAC$0.136

→

Avg plan cost$0.283

Part D spend $38.8M 2× spread, current vs floor

Class share

65%

of class CY24 spend

View profile →

Medroxyprogesterone

Brand: Depo-Provera · 589K Part D claims (CY24) · 191K beneficiaries · First FDA approval: 1959-06-03

6 generic mfrs 0 plans require PA

Low NADAC$0.118

→

Avg plan cost$16.30

Part D spend $12.6M 138× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Norethindrone

Brand: Affodel · 219K Part D claims (CY24) · 75K beneficiaries · First FDA approval: 2001-05-25

11 generic mfrs 0 plans require PA

Low NADAC$0.094

→

Avg plan cost$0.145

Part D spend $6.1M 2× spread, current vs floor

Class share

10%

of class CY24 spend

View profile →

Levonorgestrel

Brand: Kyleena · 1K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2009-10-01

Brand-only (no generics) 5 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.4M

Class share

of class CY24 spend

View profile →

Etonogestrel

Brand: Nexplanon · 881 Part D claims (CY24) · 875 beneficiaries · First FDA approval: 2021-06-01

Brand-only (no generics) 2 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $1.0M

Class share

of class CY24 spend

View profile →

Desogestrel and Ethinyl Estradiol

Brand: AVERI · — Part D claims (CY24) · First FDA approval: 1999-10-22

11 generic mfrs 0 plans require PA

Low NADAC$0.135

→

Avg plan cost$0.179

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Desogestrel and Ethinyl Estradiol and Ethinyl Estradiol

Brand: SIMLIYA · — Part D claims (CY24) · First FDA approval: 2012-04-04

Brand-only (no generics)

Low NADAC$0.149

→

Avg plan cost$0.149

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Drospirenone and Ethinyl Estradiol

Brand: Jasmiel · — Part D claims (CY24) · First FDA approval: 2001-05-11

11 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.154

→

Avg plan cost$0.666

Part D spend — 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Ethynodiol Diacetate and Ethinyl Estradiol

Brand: Kelnor 1/35 · — Part D claims (CY24) · First FDA approval: 2005-06-20

4 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.313

→

Avg plan cost$0.526

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Norgestimate and Ethinyl Estradiol

Brand: Estarylla · — Part D claims (CY24) · First FDA approval: 2002-09-26

10 generic mfrs 0 plans require PA

Low NADAC$0.105

→

Avg plan cost$0.122

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.